This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.

This study has been completed.
Information provided by (Responsible Party):
Janssen-Cilag B.V. Identifier:
First received: February 26, 2007
Last updated: April 15, 2015
Last verified: April 2015
The primary aim of this observational study is to collect safety and effectiveness data for bortezomib used at first relapse in a group of multiple myeloma patients who received specific and well defined first line treatments within previous clinical studies.

Condition Intervention Phase
Multiple Myeloma Hematological Neoplasms Drug: Bortezomib Phase 4

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: An Observational Study To Determine Velcade (Bortezomib) Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies (ADVANCE)

Resource links provided by NLM:

Further study details as provided by Janssen-Cilag B.V.:

Primary Outcome Measures:
  • Response to treatment [ Time Frame: No timepoints have been defined, as this is an observational study; data will be collected until three years after latest bortezomib administration ]

Secondary Outcome Measures:
  • bortezomib treatment schedule, dosing and timing [ Time Frame: each cycle ]
  • combination therapies for multiple myeloma [ Time Frame: from start of bortezomib treatment up to 30 days after last bortezomib administration ]
  • adverse events [ Time Frame: from start of bortezomib treatment up to 30 days after last bortezomib administration ]
  • overall survival [ Time Frame: from end of bortezomib treatment up to 3 years after last bortezomib administration ]

Enrollment: 11
Study Start Date: September 2006
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Bortezomib dose as determined (observational study) by treating physician
Drug: Bortezomib
dose as determined (observational study) by treating physician

Detailed Description:
There is a need by physicians to evaluate the results of bortezomib treatment in a homogenous patient population with regard to the multiple myeloma treatments in first line. For that reason the current study, ADVANCE, is designed to structurally collect data on the daily practice use of bortezomib as treatment after first relapse in patients with specific and well defined first line treatments (i.e. patients who participated in the HOVON-49 or HOVON-50 study). In both HOVON studies patients were randomized to either receiving thalidomide or not, as a part of the first line treatment. Therefore, the effect of pre-treatment with thalidomide on duration, effectiveness and safety of the bortezomib treatment after first relapse can be studied specifically. The analysis of this particular type of data will, however, be descriptive. All adverse events, regardless of seriousness, severity, or presumed relationship to bortezomib therapy will be recorded on the case report form, i.e., a form for each patient in the study on which all needed data are recorded, and reported to the sponsor within current timelines. The sponsor assumes responsibility for appropriate reporting of adverse events to the regulatory authorities. This project is a 'post authorization study (PAS)'. This means that only routinely available medical data are collected, with the patients' permission, and no additional interventions or diagnostic procedures should be done specifically for this study. Because the study is observational, dosage, administration and duration of treatment is at discretion of the treating physician

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Multiple Myeloma patients treated with bortezomib at first relapse after participation in first line HOVON 49 or 50 clinical studies

Inclusion Criteria:

  • Patients have to sign a statement that they agree with collection of their clinical data for this project
  • patients had a first relapse or progressive disease after treatment in the HOVON-49 or HOVON-50 study and will be treated with bortezomib.

Exclusion Criteria:

  • Prior enrollment in HOVON-54 study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00440479

Bergen Op Zoom, Netherlands
Breda, Netherlands
Ede Gld, Netherlands
Nijmegen, Netherlands
Rotterdam, Netherlands
Terneuzen, Netherlands
Tilburg, Netherlands
Utrecht, Netherlands
Vlissingen, Netherlands
Sponsors and Collaborators
Janssen-Cilag B.V.
Study Director: Janssen-Cilag B.V. Clinical Trial Janssen-Cilag B.V.
  More Information

Responsible Party: Janssen-Cilag B.V. Identifier: NCT00440479     History of Changes
Other Study ID Numbers: CR012361
Study First Received: February 26, 2007
Last Updated: April 15, 2015

Keywords provided by Janssen-Cilag B.V.:
Multiple Myeloma
hematological neoplasms
proteasome inhibitor

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Hematologic Neoplasms
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Neoplasms by Site
Antineoplastic Agents processed this record on September 20, 2017